1	Association of pitavastatin use with bone markers and bone mineral				
2	density in postmenopausal women				
3	Jihye Hyun, Minji Sohn, Hyeran Oh, Soo Lim				
4					
5	Department of Internal Medicine, Seoul National University College of Medicine and Seoul				
6	National University Bundang Hospital, Seongnam, South Korea				
7					
8					
9	* Corresponding author: Soo Lim, MD, PhD				
10	Department of Internal Medicine, Seoul National University College of Medicine and Seoul				
11	National University Bundang Hospital				
12	300, Gumi-dong, Bundang-gu, Seongnam, Korea (postal code: 463-707)				
13	E-mail: limsoo@snu.ac.kr Tel: 82-31-787- 7035 / Fax: 82-31-787-4052				
14					
15	• Short title: Pitavastatin and Bone Health in Postmenopausal Women				
16	• Number of Tables and figures: 4 tables and 2 figures (4 supplementary tables)				
17	• Word counts: 5,735 words				
18	• Trial registration: NCT06359353				
19					

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 Abstract

BACKGROUND: The study aimed to evaluate the effects of pitavastatin therapy on
biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal
women with osteopenia or osteoporosis and hypercholesterolemia.

24 METHODS AND RESULTS: This prospective observational study recruited 70 postmenopausal Korean women who were administered pitavastatin. Changes in BMD at the 25 26 femoral neck (FN), total hip (TH), and lumbar spines (LS), as well as laboratory values related to bone turnover markers and lipid profiles, including lipoprotein subfractions, were 27 assessed over 12 months. BMD was further observed during regular clinic visits up to 4 years. 28 A total of 67 patients completed 12 months of pitavastatin therapy. There were no significant 29 30 changes in BMD (-0.001 ± 0.026 at FN, -0.005 ± 0.032 at TH, and 0.002 ± 0.037 at LS; all 31 Ps > 0.05). Bone markers did not change except for procollagen type 1 N-propeptide (P1NP), which slightly decreased (-4.0 ± 10.3 , P < 0.05). Low-density lipoprotein (LDL) cholesterol 32 33 levels decreased by 36% to 39% from baseline, and the LDL subfraction score decreased 34 from 2.85 ± 1.79 to 1.80 ± 0.63 (P < 0.001). During the extended observation period, BMD at FN and TH decreased by 0.85% and 1.69% per year, respectively, while BMD at the LS was 35 preserved. 36

37 CONCLUSIONS: In postmenopausal women with osteopenia or osteoporosis requiring 38 lipid-lowering therapy, one year of pitavastatin maintained BMD and effectively controlled 39 cholesterol levels. BMD changes during statin therapy were more favorable than the natural 40 decline. These findings suggest pitavastatin can be safely used in menopausal women without 41 compromising bone health.

42 Keywords: Pitavastatin, BMD, osteoporosis, bone markers

44 Introduction

Statins, primarily used to lower cholesterol levels and prevent cardiovascular diseases, have 45 been investigated for their additional effects on bone health.¹ A statin was associated with a 46 lower risk of fractures in the elderly from a UK national database,² while other studies 47 reported conflicting results, showing no effect on fractures in postmenopausal women or even 48 worsening bone mineral density (BMD) in type 2 diabetes.^{3,4} These indicate that statins needs 49 to be used cautiously and tailored to specific cases based on the type of statins. Given the 50 growing prevalence of osteoporosis in aging populations who might also require statins, the 51 52 relationship between statins and bone health needs further evidence.

Osteoporosis is a skeletal disorder characterized by weakened bone strength and is increasingly prevalent in rapidly aging societies.⁵ Traditional risk factors for osteoporosis include aging, hormonal changes, inadequate dietary calcium and vitamin D, and some medications.⁶ The major determinant of bone loss in women during middle age is menopause,⁷ but concomitant long-term medication may affect their bone health.

A systematic review and meta-analysis of 33 clinical trials found that statin treatment was associated with increased BMD at the total hip (TH) and lumbar spines (LS), and improved the bone formation marker, such as osteocalcin, while having a neutral effect on BMD at the femoral neck (FN), bone-specific alkaline phosphatase, and C-terminal telopeptide (CTX).⁸ Most of the findings were from observational studies, with limited randomized controlled trials showing a neutral effect on BMD.

Pitavastatin has moderate-intensity cholesterol-lowering effects⁹ and a long duration of action, providing convenience to patients regardless of the time of administration.¹⁰ With minimal metabolism through the cytochrome P450 enzymes, pitavastatin is primarily metabolized through UDP-glucuronosyltransferase enzymes and has reduced potential for drug interaction.^{10,11} These characteristics might be beneficial for the elderly who might use 69 multiple medications from the aspect of drug-drug interaction.

70 In this study, we aimed to investigate the effects of pitavastatin therapy on bone health in

71 postmenopausal women with osteopenia or osteoporosis and concurrent hypercholesterolemia.

72 We expected to provide valuable insights into its potential effects on patients with osteopenia

- 73 or osteoporosis and hypercholesterolemia.
- 74

75 Patients and Methods

76 Data Availability Statement

The datasets collected and investigated in this study are available from the correspondingauthor upon a reasonable request.

79

80 Study Design and Setting

This study was designed as a prospective, single-arm, open label study and was approved by an independent ethics committee/Institutional Review Board (B-1902-520-004). It was registered at clinicaltrials.gov (NCT06359353) and conducted at Seoul National University Bundang Hospital. All participants provided written informed consent prior to participating in the study.

Our study size of 70 participants was set based on a reference study¹² that reported a significant reduction in serum N-terminal telopeptide of type 1 collagen (NTX) from $15.53 \pm$ 4.2 nM BCE/mM Cr to 12.06 ± 2.6 nM BCE/mM Cr after three months of pitavastatin treatment. We targeted 66 participants, accounting for a 10% dropout rate. We included postmenopausal women aged 75 years or younger. Eligibility was confirmed through initial screenings and medical records review, focusing on patients who were diagnosed with

92 osteopenia or osteoporosis ($-3.0 \le T$ -score ≤ -1.5), initiating pitavastatin treatment for 93 hypercholesterolemia for the first time, and presenting with baseline bone resorption markers 94 (CTX ≥ 0.300 ng/mL or urinary NTX > 16.5 nM BCE/mM Cr).

Patients were excluded based on the following criteria: (1) history of statin use for more than one month within the three months prior to the study; (2) treatment with oral or injectable glucocorticoids for over one week in the same period; (3) current use of thiazolidinediones; (4) ongoing treatment for malignant tumors.

99 All participants received pitavastatin orally at a daily dosage of 4 mg for 52 weeks or 100 more. While most patients maintained the dosage of 4 mg of pitavastatin once daily 101 throughout the study period, the dosage was decreased to 2 mg daily at physician's discretion.

102

103 Variables and Outcome Measurements

The primary outcome was the change in BMD after 12 months of pitavastatin therapy. Secondary outcomes included the changes in osteocalcin, procollagen type 1 N-terminal propeptide (P1NP), CTX, and NTX after 6 and 12 months. Additionally, laboratory values related to patients' general status, including cholesterol levels, glycated haemoglobin (HbA1c), liver and kidney function, as well as those related to bone mineral metabolism such as 25-hydroxyl-vitamin D (250H-vitamin D) and parathyroid hormone (PTH) levels, were assessed at 3, 6 and 12 months.

BMD was measured using dual-energy X-ray absorptiometry (DXA) with a QDR 4500 device (Hologic, Waltham, MA, USA). We also used the T-score, which compares an individual's BMD with the mean value for young, normal women and expresses the differences as a standard deviation score.¹³ Changes in BMD and T-scores from baseline to 12 months post-treatment at the following sites: left hip (including FN, TH), and LS (L1, L2,

L3, L4, and the average from L1 to L4) were observed. BMD was further investigated as part
of an extended protocol in year 2, and also collected if examined during regular clinic visits
for up to 4 years.

Body composition including body weight, height, and body mass index (BMI), was measured by standard methods with the participants wearing light clothing.

Biochemical markers of bone metabolism were measured: Osteocalcin and P1NP levels using the Elecsys N-MID Osteocalcin and Total P1NP assays (Roche), respectively. Urine NTX and CTX levels were assessed via an NTX ELISA kit (Inverness Medical) and the Elecsys B-CrossLaps assay (Roche). Serum calcium, phosphorus, 25OH-vitamin D, and PTH were evaluated using colorimetry (Hitachi 747), HPLC (Variant II Turbo, Bio-Rad), and chemiluminescence (LIAISON; DiaSorin), respectively.

Plasma glucose and HbA1c were determined using the glucose oxidase method (Hitachi
747) and HPLC (Variant II Turbo). Serum AST, ALT, creatinine, and eGFR were measured
with the Architect Ci8200 (Abbott). Cholesterol profiles were analyzed with Hitachi's
Clinical Chemistry Analyzer. Urinary albumin and creatinine were quantified by turbidimetry
(502X, A&T) and the Jaffe method (Hitachi 7170).

Lipoprotein subfractions were also measured using the Quantimetrix LDL Lipoprint System (Quantimetrix Corporation, Redondo Beach, CA, USA) following the manufacturer's instructions.¹⁴ This method used high-resolution polyacrylamide gel electrophoresis to separate and measure very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and LDL subfractions. IDL was divided into large (C), medium (B), and small (A) subfractions. The LDL subfraction score was calculated using the weighted area under the curve (AUC) of LDLs.

139

140 Statistical Analysis

141 All patients in the study were enrolled in the analysis. Clinical characteristics are presented as means \pm standard deviation (SD). To compare baseline and post-treatment values across all 142 successive pairs during the follow-up period for each patient, we used paired t-tests to 143 analyze changes in clinical variables. The mean annual percent change in BMD was 144 calculated by dividing the difference between the baseline BMD and follow-up measurements 145 of BMD by the baseline BMD, then dividing by the study period (in years) and multiplying 146 147 by 100. Additionally, we analyzed over 4 years (1,614 days) of observations to compare the fitted slope of BMD changes in our cohort with those reported in other long-term studies (4 148 149 years or more) on postmenopausal women who had no history of treatments affecting bone 150 health, aiming to compare with natural BMD changes. A t-test was conducted to compare our estimated slope, derived from a simple linear regression model, with the average slopes of the 151 152 international and Korean cohorts. For data management, participants who did not take their prescribed diabetes medication during the study period were excluded from the glucose level 153 analysis. Also, BMD and T-score values that were deemed inappropriate due to specific 154 155 reasons such as pin fixation, cement injection, etc., were excluded from the analysis, to account for variations in personal examination. 156

All statistical analyses were conducted using R software, version 4.3.3 (R Foundation
for Statistical Computing, Vienna, Austria). A *P*-value of < 0.05 was considered statistically
significant, indicating evidence of a meaningful difference.

160

161 **Results**

162 Baseline Characteristics of Study Participants

A total of 70 patients with an average age of 65.3 ± 5.3 years were enrolled (**Table S1**). The most common underlying diseases were diabetes (31.4%), osteopenia (30%), and hypothyroidism (22.9%). The lipid profiles of the study group showed a total cholesterol

- 166 levels of $229 \pm 35 \text{ mg/dL}$, triglyceride levels of $127 \pm 54 \text{ mg/dL}$, and LDL-cholesterol levels 167 of $145 \pm 25 \text{ mg/dL}$. The serum 25OH-vitamin D levels averaged $26.2 \pm 10.1 \text{ ng/mL}$.
- 168

169 Changes in Lipid Profiles and Biochemical Parameters over 12 months

170*Tables 1* and 2 present the changes in lipid profiles and biochemical parameters in 67 patients171who received 12 months of pitavastatin treatment. LDL-cholesterol levels decreased from172 $145.7 \pm 24.1 \text{ mg/dL}$ to $89.1 \pm 20.2 \text{ mg/dL}$ at 6 months and to $93.7 \pm 30.1 \text{ mg/dL}$ at 12 months,173showing declines of 38.8% and 35.7%, respectively. Four people reduced their dosage from 4174mg to 2 mg (*Table 1*). Remnant cholesterol, triglycerides, VLDL, IDL-C, IDL-B, IDL-A, and175LDL particles (LDL Large 1 to LDL Small 5) also decreased during the 1-year observation (*P*176< 0.001 for all time points).</td>

The 25OH-vitamin D and PTH levels increased from baseline to 12 months (P = 0.012and P = 0.038, respectively) (*Table 1*), while calcium levels did not change over the 12 months.

180

181 BMD and T-score Changes with Bone Turnover Markers over 12 months

BMD measurements at all sites—FN, TH, and LS—showed no significant changes over 12

months (*Table 3*): a -0.16% decrease in BMD at FN (absolute change: -0.001 ± 0.026), a -0.66% decrease at TH (absolute change: -0.005 ± 0.032), and a 0.26\% increase at LS (absolute change: 0.002 ± 0.037). Similarly, T-scores also did not show significant changes at any site. Although T-scores at the LS showed slight increases with absolute changes ranging from 0.03 to 0.08, these changes were not statistically significant.

188 The time-dependent changes in bone turnover markers over a period of 6 and 12 months 189 are shown in *Figure 1*. There was no significant change in osteocalcin and the bone

resorption markers, NTX and CTX, at the 6-month and 12-month marks (*Figure 1A, 1C* and *1D*). Conversely, a significant decrease in the bone formation marker P1NP was observed (*Figure 1B*, both P < 0.05).

193

194 **Extended Observations of the Participants**

At the additional follow-up, 63 patients were further evaluated at a median of 26 months (IQR 24.8-31.8). Laboratory values and BMD changes at the third visit are detailed in **Table S2** and **S3**. The decrease in lipid parameters, including total cholesterol, LDL-cholesterol, and triglycerides, was maintained continuously in the extended observation (all *Ps* < 0.001). However, HDL-cholesterol did not change significantly. Additionally, 25OH-vitamin D levels showed a significant increase from baseline to the 26-month follow-up (*P* < 0.001).

In assessing changes in BMD and T-scores over an extended period, we observed significant decreases at the FN: absolute change in BMD was -0.011 ± 0.032 (-0.85%/year, P= 0.013), and in the T-score was -0.12 ± 0.36 (-3.01%/year, P = 0.011); and at the TH: the absolute change in BMD was -0.027 ± 0.055 (-1.69%/year, P < 0.001), and in the T-score was -0.24 ± 0.39 (-10.03%/year, P < 0.001). No statistically significant changes were noted at the LS.

Furthermore, we indirectly compared our extended data, which includes examination 207 beyond the second visit year up to four years, with longitudinal studies conducted over 4 208 209 years or more on postmenopausal women from five international and two Korean cohorts (Table S4). The estimated slope of our cohort, along with the average slopes of international 210 (FN: -0.010, TH: -0.014, LS: -0.021) and Korean (FN: -0.008, TH: -0.008, LS: -0.001) 211 212 cohorts at each site, are presented in Figure 2. The slopes of the linear fitted unadjusted models for our cohort at the FN ($\beta = -0.003$, SE = 0.001, P = 0.025), TH ($\beta = -0.005$, SE = 213 0.002, P = 0.004), and LS ($\beta = 0.001$, SE = 0.002, P = 0.862) showed significant differences 214

from the average slopes of the international cohorts (all Ps < 0.05). However, compared to the Korean cohorts, the fitted linear slopes for our cohort were not significantly different at the TH (P = 0.146) and LS (P = 0.937).

218

219 Safety and Tolerability

A total of 29 (41.4%) patients experienced adverse events, most of which were mild severity. The most frequent adverse events (AEs) were musculoskeletal disorders, affecting 13 (17.1%) of patients. All patients continued the medication, with two patients reducing the dosage due to mild myalgia. Eight patients reported gastrointestinal disorders, while three experienced urinary disorders. One spinal fracture was observed as a result of a fell on an icy road, and one serious adverse event, hospitalization due to cholangitis, was observed during the study period. Adverse events summarized by organ in the participants are shown in *Table 4*.

227

228 **Discussion**

In our study, postmenopausal women with osteopenia or osteoporosis treated with 229 pitavastatin exhibited no significant changes in BMD at FN, TH, and LS sites during the first 230 231 year. Additionally, pitavastatin therapy significantly reduced LDL-cholesterol levels and LDL subfraction scores, also benefiting cardiovascular risk. The reduction in small, LDL 232 subfraction levels after pitavastatin therapy is a new finding in the current study.¹⁵ Our 233 findings suggest that pitavastatin is a favorable option for treating dyslipidemia and does not 234 negatively affect BMD or worsen the severity of osteopenia or osteoporosis in 235 postmenopausal women. 236

Long-term use of pitavastatin therapy was found to be safe in the context of BMD changes compared to the natural decline observed in postmenopausal women (**Table S4** and **Figure S1**).^{7,16,17} After one year of pitavastatin treatment, the percentage changes in BMD

240 were -0.16%/year at the FN, -0.66%/year at the TH, and 0.26%/year at the LS. These changes were similar or less severe than natural declines reported in previous studies.¹⁶⁻¹⁹ The 241 Framingham Osteoporosis Study, which included postmenopausal women aged 67-95 years, 242 showed declines in BMD of -0.87%/year at the FN during a 4-year follow-up period.¹⁹ A 243 study in Denmark that investigated BMD changes over a 2-year interval in postmenopausal 244 women aged 60-69 years without conditions affecting bone metabolism, revealed a BMD 245 decrease of -0.40%/2 years in the TH and an increase of 0.50%/2 years in the LS.¹⁸ Two 246 Korean prospective studies reported annual BMD changes of -0.67% and -0.87% at the FN, 247 248 -0.66% and 0.95% at the TH, and -0.18% and 0.27% at the LS sites, respectively, among elderly women without osteoporosis treatment.¹⁶ Compared to these studies, our study 249 250 showed a smaller decrease at the FN and TH in postmenopausal women with similar age 251 ranges, suggesting pitavastatin may have a neutral or slightly positive effect on bone metabolism. 252

Preclinical investigations have shown that stating possess anabolic effects on bone by 253 diminishing the synthesis of mevalonate and impairing protein prenylation, thereby 254 stimulating bone morphogenetic protein-2.²⁰ However, clinical studies have shown varied 255 effects depending on specific conditions. In a case-control study, in women under 70 years, 256 statin use is associated with decreased osteoporosis rates, likely due to their osteogenic 257 effects, such as promoting osteoblast differentiation and inhibiting osteoclast activation.²¹ 258 259 Conversely, in women aged 70 years and above, statin use was associated with higher osteoporosis rates, possibly due to the estrogen-lowering effects of statins, which increase 260 bone resorption and reduce bone density.^{8,22} 261

Most studies investigating the effects of statins on BMD had relatively short durations, such as one year. Twelve-month treatment of simvastatin 20 mg did not change BMD at the FN and LS in 32 postmenopausal subjects with an average age of 56.8 years and a BMI of

265 $29.3 \pm 4.5 \text{ kg/m}^{2.23}$ Similarly, in a study involving 318 postmenopausal participants with 266 osteopenia, aged 40-75 years, who were randomly assigned to receive a once-daily dose of 267 atorvastatin (10, 20, 40, or 80 mg) or a placebo, there were no significant changes in BMD at 268 the FN and LS in any treatment group.²⁴ Thus, studies investigating the efficacy and safety of 269 statins on bone health have been limited and varied in study design, making it difficult to 270 draw definitive conclusion.

The studies investigating the effects of statins on bone formation and resorption markers have also been limited, yielding mixed results. Osteocalcin levels initially increased and then decreased, indicating the transient effects of statins on bone metabolism. One study reported that a four-week treatment with 20 mg of simvastatin increased osteocalcin levels,²⁵ but this positive effect was attenuated with longer treatment durations.²³ In contrast, our study did not observe any significant changes in osteocalcin levels.

277 Regarding P1NP, our study showed a significant decrease over 12 months. This finding 278 aligns with a cohort study of 500 statin users (age 67 ± 10 years, BMI 29.7 ± 4.1 kg/m²). 279 Among these users, 81 individuals on stable doses of statins (pravastatin, lovastatin, 280 fluvastatin, simvastatin, or atorvastatin) for less than a year exhibited significantly lower 281 P1NP levels compared to 1,931 non-users with similar age and BMI.²⁶

In a recent randomized study with 24 postmenopausal women, a statistically significant 282 decrease in NTX was observed in patients receiving rosuvastatin (5 to 10 mg) but not in those 283 receiving atorvastatin 20 mg.²⁷ A meta-analysis with 5 studies reported that statin treatment 284 decreased NTX levels (-1.14 nM BCE, 95% CI: -1.21, -0.07).²⁸ Experimental studies 285 reported suppressed osteoclast formation 286 that statins treatment through the osteoprotegerin/receptor activator of nuclear factor kappa-B (NFKB) ligand/receptor 287 activator of NFKB.^{29,30} Significantly, our study found no changes in NTX and CTX levels 288 after one year of pitavastatin treatment, indicating that pitavastatin may not increase bone 289

resorption, potentially stabilizing the overall bone turnover rate in postmenopausal women.

In a randomized controlled trial, disparate effects of statins on 25OH-vitamin D levels 291 were reported: over an 8-week treatment period, 10 mg of rosuvastatin increased these levels, 292 whereas 80 mg of fluvastatin did not.³¹ Despite both dosages having equivalent drug 293 potencies, their effects on vitamin D levels differed, suggesting that the impact of statin 294 therapy on vitamin D levels might be inconsistent. The underlying mechanism remains 295 unclear but likely involves the metabolism of vitamin D by CYP3A4 and CYP3A5 enzymes 296 in the liver and intestines-pathways heavily utilized by statins, which could indicate a 297 possible positive influence on vitamin D levels.³² Furthermore, in our study, 25OH-vitamin D 298 levels increased significantly over two years. Among these participants, 24 patients (35.3%) 299 regularly took vitamin D and calcium supplements, which remained unchanged during the 300 301 study period. Although the exact mechanisms by which statins affect vitamin D metabolism are not fully determined,³³ this could contribute beneficially to statin's impact on bone health. 302 Taken together, given the variety of factors such as statin type, dosage, treatment duration, 303 304 and patient characteristics influencing the effects of statins on bone metabolism, welldesigned and larger studies are essential to provide definitive results. 305

In our study, we observed a reduction in LDL-cholesterol levels by 36-39% following 306 the administration of 4 mg of pitavastatin. Furthermore, it decreased non-HDL-cholesterol 307 308 levels from 167.4 ± 28.2 mg/dL at baseline to 111.6 ± 33.0 mg/dL at the 12-month follow-up. 309 Similarly, in the REAL-CAD study, daily administration of 4 mg of pitavastatin significantly reduced cardiovascular events in 13,054 Japanese patients with stable coronary artery disease 310 (HR = 0.81, 95% CI 0.69-0.95).³⁴ A decreased LDL subfraction score due to pitavastatin 311 treatment, as found in our current study, reinforces the effectiveness of reducing 312 cardiovascular risks. An additional benefit of pitavastatin is its demonstrated lower risk of 313 new-onset diabetes mellitus compared to atorvastatin or rosuvastatin.^{35,36} 314

In the current study, a control group was not included. However, establishing a nomedication group could be challenging, as all women with hypercholesterolemia require lipid-lowering medication. Instead, we compared the BMD changes in our study to those observed in population from both Asian as well as Western cohorts with longitudinal observations.

320

321 Conclusions

322 Our study suggests that pitavastatin therapy can be an ideal option for treating dyslipidemia

in postmenopausal women with osteopenia or osteoporosis, without adversely affecting bone

health over a period of up to 4 years.

326 Affiliations

- 327 Department of Internal Medicine, Seoul National University College of Medicine, Seoul
- 328 National University Bundang Hospital, Seongnam, South Korea (J.H., M.S., H.O., S.L.).

329 Source of Funding

- 330 This work was supported, in part, by grants from Seoul National University Bundang
- 331 Hospital (B-1902-320-004) and JW Pharmaceutical (06-2019-0128).

332 **Disclosures**

333 None.

334 Supplementary Material

Tables S1-S2

337 **References**

- Gonyeau MJ. Statins and osteoporosis: a clinical review. *Pharmacotherapy*. 2005;25:228-243.
 doi: 10.1592/phco.25.2.228.56954
- Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors
 and the risk of fractures. *JAMA*. 2000;283:3205-3210. doi: 10.1001/jama.283.24.3205
- LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE,
 McNeeley SG, Passaro MD, et al. Statin use, clinical fracture, and bone density in
 postmenopausal women: results from the Women's Health Initiative Observational Study.
 Ann Intern Med. 2003;139:97-104. doi: 10.7326/0003-4819-139-2-200307150-00009
- Wada Y, Nakamura Y, Koshiyama H. Lack of positive correlation between statin use and
 bone mineral density in Japanese subjects with type 2 diabetes. *Arch Intern Med.* 2000;160:2865. doi: 10.1001/archinte.160.18.2865
- Ahn SH, Park SM, Park SY, Yoo JI, Jung HS, Nho JH, Kim SH, Lee YK, Ha YC, Jang S, et al.
 Osteoporosis and Osteoporotic Fracture Fact Sheet in Korea. *J Bone Metab.* 2020;27:281 290. doi: 10.11005/jbm.2020.27.4.281
- Sozen T, Ozisik L, Basaran NC. An overview and management of osteoporosis. *Eur J Rheumatol.* 2017;4:46-56. doi: 10.5152/eurjrheum.2016.048
- Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, Lo JC,
 Johnston JM, Cauley JA, Danielson ME, et al. Bone mineral density changes during the
 menopause transition in a multiethnic cohort of women. *J Clin Endocrinol Metab.* 2008;93:861-868. doi: 10.1210/jc.2007-1876
- An T, Hao J, Sun S, Li R, Yang M, Cheng G, Zou M. Efficacy of statins for osteoporosis: a
 systematic review and meta-analysis. *Osteoporos Int.* 2017;28:47-57. doi: 10.1007/s00198 016-3844-8
- Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb
 CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA Guideline on the Primary
 Prevention of Cardiovascular Disease: Executive Summary: A Report of the American
 College of Cardiology/American Heart Association Task Force on Clinical Practice
 Guidelines. J Am Coll Cardiol. 2019;74:1376-1414. doi: 10.1016/j.jacc.2019.03.009
- 36610.Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005;59:239-252. doi:36710.1111/j.1742-1241.2005.00461.x
- Fujino H, Yamada I, Shimada S, Yoneda M, Kojima J. Metabolic fate of pitavastatin, a new
 inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in
 lactonization. *Xenobiotica*. 2003;33:27-41. doi: 10.1080/0049825021000017957
- Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.
 Short-term effects of pitavastatin on biochemical markers of bone turnover in patients
 with hypercholesterolemia. *Intern Med.* 2007;46:1967-1973. doi:
 10.2169/internalmedicine.46.0419

- 375 13. Diab DL, Watts NB. Diagnosis and treatment of osteoporosis in older adults. *Endocrinol* 376 *Metab Clin North Am.* 2013;42:305-317. doi: 10.1016/j.ecl.2013.02.007
- Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, McConnell JP.
 Development of a rapid, quantitative method for LDL subfractionation with use of the
 Quantimetrix Lipoprint LDL System. *Clin Chem.* 2001;47:266-274.
- Statins do not decrease small, dense low-density lipoprotein. *Tex Heart Inst J.* 2010;37:421428.
- Park SY, Kim JH, Choi HJ, Ku EJ, Hong AR, Lee JH, Shin CS, Cho NH. Longitudinal changes
 in bone mineral density and trabecular bone score in Korean adults: a community-based
 prospective study. *Arch Osteoporos.* 2020;15:100. doi: 10.1007/s11657-020-00731-6
- Lim Y, Jo K, Ha HS, Yim HW, Yoon KH, Lee WC, Son HY, Baek KH, Kang MI. The prevalence
 of osteoporosis and the rate of bone loss in Korean adults: the Chungju metabolic disease
 cohort (CMC) study. *Osteoporos Int.* 2017;28:1453-1459. doi: 10.1007/s00198-016-3893-z
- Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men
 and women: a longitudinal study. *Osteoporos Int.* 2002;13:105-112. doi:
 10.1007/s001980200001
- Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW, Kiel DP. Risk
 factors for longitudinal bone loss in elderly men and women: the Framingham
 Osteoporosis Study. *J Bone Miner Res.* 2000;15:710-720. doi: 10.1359/jbmr.2000.15.4.710
- 39520.Zhang Y, Bradley AD, Wang D, Reinhardt RA. Statins, bone metabolism and treatment of396bone catabolic diseases. *Pharmacol Res.* 2014;88:53-61. doi: 10.1016/j.phrs.2013.12.009
- 397 21. Kim SY, Yoo DM, Min C, Kim JH, Kwon MJ, Kim JH, Choi HG. Association between
 398 Osteoporosis and Previous Statin Use: A Nested Case-Control Study. *Int J Environ Res*399 *Public Health.* 2021;18. doi: 10.3390/ijerph182211902
- Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ,
 Miller SS, Mulloy AL, et al. Alendronate and estrogen effects in postmenopausal women
 with low bone mineral density. Alendronate/Estrogen Study Group. *J Clin Endocrinol Metab.* 2000;85:720-726. doi: 10.1210/jcem.85.2.6393
- Tikiz C, Tikiz H, Taneli F, Gumuser G, Tuzun C. Effects of simvastatin on bone mineral
 density and remodeling parameters in postmenopausal osteopenic subjects: 1-year followup study. *Clin Rheumatol.* 2005;24:447-452. doi: 10.1007/s10067-004-1053-x
- 407 24. Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR.
 408 Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double409 blind, placebo-controlled, dose-ranging trial. *J Clin Endocrinol Metab.* 2007;92:4671-4677.
 410 doi: 10.1210/jc.2006-1909
- 411 25. Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW. Simvastatin increases serum
 412 osteocalcin concentration in patients treated for hypercholesterolaemia. *J Clin Endocrinol*413 *Metab.* 2001;86:4556-4559. doi: 10.1210/jcem.86.9.8001
- 414 26. Hernandez JL, Olmos JM, Romana G, Martinez J, Castillo J, Yezerska I, Ramos C, Gonzalez-

415 Macias J. Bone turnover markers in statin users: a population-based analysis from the 416 Camargo Cohort Study. *Maturitas*. 2013;75:67-73. doi: 10.1016/j.maturitas.2013.02.003

- 417 27. Braszak-Cymerman A, Walczak MK, Oduah MT, Ludziejewska A, Bryl W. Comparison of the
 418 pleiotropic effect of atorvastatin and rosuvastatin on postmenopausal changes in bone
 419 turnover: A randomized comparative study. *Medicine (Baltimore)*. 2024;103:e38122. doi:
 420 10.1097/MD.00000000038122
- 28. Zhao H, Tang Y, Zhen Y, Qi C, Chen S. The effect of statins on bone turnover biomarkers: a
 systematic review and meta-analysis of randomized controlled trials. *Endocr J.*2023;70:473-480. doi: 10.1507/endocrj.EJ22-0512
- 424 29. Sun X, Wei B, Peng Z, Fu Q, Wang C, Zhen J, Sun J. Protective effects of Dipsacus asper polysaccharide on osteoporosis in vivo by regulating RANKL/RANK/OPG/VEGF 425 and 426 PI3K/Akt/eNOS pathway. Int Biol Macromol. 2019;129:579-587. 1 doi: 427 10.1016/j.ijbiomac.2019.02.022
- 428 30. Elewa HF, El-Remessy AB, Somanath PR, Fagan SC. Diverse effects of statins on
 429 angiogenesis: new therapeutic avenues. *Pharmacotherapy*. 2010;30:169-176. doi:
 430 10.1592/phco.30.2.169
- 431 31. Ertugrul DT, Yavuz B, Cil H, Ata N, Akin KO, Kucukazman M, Yalcin AA, Dal K, Yavuz BB,
 432 Tutal E. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin
 433 treatment on the levels of 25 hydroxyvitamin D. *Cardiovasc Ther.* 2011;29:146-152. doi:
 434 10.1111/j.1755-5922.2010.00141.x
- 32. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T, Kalhorn TF, Watkins PB,
 Schuetz EG, Thummel KE. Intestinal and hepatic CYP3A4 catalyze hydroxylation of
 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. *Mol Pharmacol.* 2006;69:56-65. doi: 10.1124/mol.105.017392
- 439 33. Mazidi M, Rezaie P, Vatanparast H, Kengne AP. Effect of statins on serum vitamin D
 440 concentrations: a systematic review and meta-analysis. *Eur J Clin Invest*. 2017;47:93-101.
 441 doi: 10.1111/eci.12698
- Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I,
 Nakagawa Y, et al. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With
 Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. *Circulation.*2018;137:1997-2009. doi: 10.1161/CIRCULATIONAHA.117.032615
- Choi JY, Choi CU, Hwang SY, Choi BG, Jang WY, Kim DY, Kim W, Park EJ, Lee S, Na JO, et al.
 Effect of Pitavastatin Compared with Atorvastatin andRosuvastatin on New-Onset Diabetes
 Mellitus in PatientsWith Acute Myocardial Infarction. *Am J Cardiol.* 2018;122:922-928. doi:
 10.1016/j.amjcard.2018.06.017
- 36. Seo WW, Seo SI, Kim Y, Yoo JJ, Shin WG, Kim J, You SC, Park RW, Park YM, Kim KJ, et al.
 Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and
 rosuvastatin: a distributed network analysis of 10 real-world databases. *Cardiovasc Diabetol.* 2022;21:82. doi: 10.1186/s12933-022-01524-6

Variable Baseline, n=67 6 months, n=67 12 months, n=67 $57.6 \pm 6.9^{*}$ Weight, kg 57.0 ± 6.7 57.0 ± 6.8 BMI, kg/m^2 23.5 ± 2.7 23.7 ± 2.9 23.5 ± 2.8 $6.1 \pm 0.7^{**}$ $6.1 \pm 0.7^{**}$ HbA1c, % 5.9 ± 0.6 $112 \pm 18^{**}$ $112 \pm 18^{**}$ Fasting glucose, mg/dL 103 ± 17 BUN, mg/dL 16 ± 4 16 ± 4 16 ± 4 Creatinine, mg/dL $0.65 \pm 0.12^{*}$ $0.66 \pm 0.12^{*}$ 0.63 ± 0.12 eGFR, mL/min/1.73 m² $90.3 \pm 9.8^{**}$ $91.2 \pm 10.1^{*}$ 93.3 ± 10.8 $4.7\pm1.1^{*}$ Uric acid, mg/dL $4.7 \pm 1.0^{*}$ 4.9 ± 1.0 Total protein, g/dL 7.3 ± 0.4 7.3 ± 0.3 7.3 ± 0.5 Total bilirubin, mg/dL 0.72 ± 0.24 $0.77 \pm 0.25^{*}$ 0.75 ± 0.24 $79 \pm 21^{*}$ $77 \pm 21^{*}$ ALP, IU/L 85 ± 21 $30 \pm 13^{*}$ AST, IU/L 26 ± 7 $28\pm8^{*}$ $29 \pm 14^{**}$ $30 \pm 19^{*}$ ALT, IU/L 23 ± 14 Bone Health and Mineral Metabolism Calcium, mg/dL 9.6 ± 0.3 9.6 ± 0.3 9.6 ± 0.3 Phosphorus, mg/dL 3.9 ± 0.4 3.9 ± 0.5 3.9 ± 0.4 $29.6 \pm 9.5^{*}$ 25OH-vitamin D, ng/mL 26.1 ± 13.3 _ $34.3 \pm 9.5^*$ PTH, pg/mL 31.4 ± 17.3 _

Table 1. Patient characteristics over 12 months

Data are mean \pm SD. Paired-T test was conducted. *P < .05, **P < .001 vs. baseline. BMI, body mass index; HbA1c, glycosylated hemoglobin; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PTH, parathyroid hormone; SD,

455

standard deviation.

Variable Baseline, n=67 6 months, n=67 12 months, n=67 $162.7 \pm 28.1^{**}$ $173.2 \pm 38.0^{**}$ Total cholesterol, mg/dL 231.4 ± 35.7 $88.7 \pm 19.9^{**}$ $94.0 \pm 30.0^{**}$ LDL-cholesterol, mg/dL 146.1 ± 24.0 64.1 ± 16.0 $61.6 \pm 16.8^*$ HDL-cholesterol, mg/dL 64.0 ± 17.4 $104.5 \pm 39.7^{**}$ $109.2 \pm 42.5^*$ Triglycerides, mg/dL 126.3 ± 54.2 Non HDL-cholesterol, mg/dL $98.6 \pm 21.4^{**}$ $111.6 \pm 33.0^*$ 167.4 ± 28.2 Remnant cholesterol, mg/dL 21.3 ± 7.2 $9.9 \pm 6.1^{*}$ $17.6 \pm 10.2^*$ Subpopulation analysis $23.2 \pm 7.1^{*}$ $24.1 \pm 8.0^{*}$ VLDL, mg/dL 31.7 ± 11.3 $15.9 \pm 4.1^{**}$ $16.4 \pm 4.0^{**}$ 24.5 ± 6.4 IDL-C, mg/dL $9.3 \pm 2.8^{**}$ $9.5\pm3.2^{\ast\ast}$ 13.5 ± 3.9 IDL-B, mg/dL $11.6 \pm 3.8^{**}$ $12.4 \pm 4.1^{**}$ IDL-A, mg/dL 15.1 ± 4.6 $31.7 \pm 10.4^{**}$ $28.6 \pm 7.7^{**}$ LDL Large-1, mg/dL 39.2 ± 15.7 $\overline{19.6 \pm 6.8}^{**}$ $23.5 \pm 10.6^{**}$ LDL Large-2, mg/dL 32.7 ± 12.4 $7.1 \pm 7.6^{**}$ $4.9 \pm 4.0^{**}$ LDL Small-3, mg/dL 14.0 ± 7.8 $1.0 \pm 2.8^{**}$ $1.4 \pm 2.9^{**}$ 6.2 ± 6.2 LDL Small-4, mg/dL $0.3 \pm 2.1^{*}$ $0.1 \pm 0.5^{*}$ LDL Small-5, mg/dL 2.1 ± 4.2 $0.0 \pm 0.1^{*}$ 0.0 ± 0.0 LDL Small-6, mg/dL 0.3 ± 1.3 LDL Small-7, mg/dL 0.0 ± 0.3 0.0 ± 0.0 0.0 ± 0.0 $1.79 \pm 0.62^{**}$ $1.79 \pm 0.50^{**}$ LDL subfraction score 2.86 ± 1.78

Tabla	2	Change	in	lir	vid	nrofilos	ovor	12	monthe
Laur	4.	Changes	111	ու	лu	promes	UVCI	14	monuis

Data are presented as mean \pm standard deviation. Paired-T test was conducted. *P <.05, **P<.001 vs. baseline.

LDL, low-density lipoprotein; HDL, high-density lipoprotein; VLDL, very low-density lipoprotein; IDL, intermediate-density lipoprotein.

			Baseline vs. 12 months				
Site of measurement	Baseline, n=67	12 months, n=67	Absolute change	Mean percent change/year (%)	^a <i>P</i> -value		
BMD, g/cm^2							
Femoral Neck	0.618 ± 0.057	0.617 ± 0.061	-0.001 ± 0.026	-0.16	0.797		
Total Hip	0.759 ± 0.063	0.753 ± 0.067	-0.005 ± 0.032	-0.66	0.201		
Lumbar Spine	0.784 ± 0.068	0.786 ± 0.063	0.002 ± 0.037	0.26	0.733		
L1	0.733 ± 0.073	0.735 ± 0.075	0.001 ± 0.040	0.14	0.773		
L2	0.767 ± 0.077	0.772 ± 0.074	0.006 ± 0.042	0.78	0.266		
L3	0.801 ± 0.079	0.810 ± 0.075	0.009 ± 0.038	1.12	0.071		
L4	0.825 ± 0.074	0.833 ± 0.067	0.008 ± 0.046	0.97	0.210		
T-score							
Femoral Neck	-1.91 ± 0.63	-1.92 ± 0.68	-0.02 ± 0.29	-1.05	0.646		
Total Hip	-1.16 ± 0.64	-1.22 ± 0.66	-0.05 ± 0.33	-4.31	0.194		
Lumbar Spine	-1.77 ± 0.62	-1.75 ± 0.58	0.03 ± 0.32	1.69	0.495		
L1	-1.76 ± 0.64	-1.74 ± 0.67	0.03 ± 0.39	1.70	0.594		
L2	-1.88 ± 0.69	-1.83 ± 0.66	0.05 ± 0.37	2.66	0.281		
L3	-1.84 ± 0.71	-1.76 ± 0.67	0.07 ± 0.35	3.80	0.110		
L4	-1.81 ± 0.67	-1.73 ± 0.59	$\overline{0.08\pm0.41}$	4.42	0.182		

 Table 3. Changes in BMD and T-score comparisons between baseline and 12 months

Data are mean \pm standard deviation. ^aPaired-T test was conducted. *P*-values < .05 were considered significant. BMD, bone mineral density.

Table 4. Adverse events

Adverse events by organ	Patients, n=70
Any adverse events - no. (%)	29 (41.4)
Musculoskeletal events - no. (%)	13 (18.5)
Back pain	2
Knee pain	2
Muscle pain	2
Myalgia	2
Ankle pain	1
Arthralgia	1
Chest pain	1
Cramp in leg	1
Shoulder pain	1
Spinal fracture	1
Tremor	1
Wrist pain	1
Gastrointestinal events - no. (%)	8 (11.4)
Dyspepsia	6
Abdominal pain	3
Anorexia	1
Enteritis	1
Epigastric pain	1
Nausea	1
Urinary events - no. (%)	3 (4.3)
Bacteriuria	1
Flank pain	1
Irregular bleeding	1
Other abnormalities- no. (%)	13 (18.5)
Edema	4

Adverse events of different organs were counted independently.

Figure legends

Figure 1. Changes in bone markers at baseline, 6 months, and 12 months. (A) Osteocalcin, (B) P1NP, (C) NTX, and (D) CTX. Data are presented as mean \pm SD. A paired-T test indicated a significant difference between the two time points (P < 0.05), as marked by an asterisk *. P1NP, procollagen type 1 N-propeptide; NTX, N-terminal telopeptide; CTX, C-terminal telopeptide; SD, standard deviation.

Figure 2. Slope of BMD changes comparing the current cohort using pitavastatin to International and Korean cohorts describing natural decline in menopausal women. (A) Femoral Neck, (B) Total Hip, (C) Lumbar Spine. The figure illustrates the BMD difference (g/cm^2) over time (years) for the current cohort (red line), with a red shaded area representing the confidence intervals of the linear fitted model. Participants in this study were observed for up to 4 years (1,614 days), including an examination beyond the second year, by visiting the regular clinic annually. An asterisk * indicates a significant difference between the estimated slope of the current cohorts (P < 0.05). The individual reference cohort slopes of the international and Korean cohorts, as described in **Table S4**, are shown as dotted lines in blue and black, respectively. The range of slopes for both international and Korean cohorts is represented as a gray shaded area.



